知镜 Cognispect · 医学文献与研究工作台

Pediatric-inspired USC-ALL regimen vs hyper-CVAD in adults with Ph-negative and Ph-like acute lymphoblastic leukemia.

Ginosyan AA, Ashouri K, Vu A, Grove S, Huang E, Hom B, Kim G, Tang B, Kolanjian A, Begur M, Nittur V, Resnick K, Hwang J, Adnani B, Ireland R, Chu M, Chaudhary P, Ali A, Siddiqi I, Woan K, Tam EL, Yaghmour G.
Leukemia research · 2026-10-13 · PMID 42879995

文献摘要

Adult acute lymphoblastic leukemia (ALL) outcomes remain inferior to pediatric results, motivating adoption of pediatric-inspired regimens (PIR) in adults. The optimal frontline regimen for high-risk subgroups, such as Philadelphia chromosome-like (Ph-like) ALL, has not been established. In this retrospective analysis, 160 adults with Philadelphia chromosome-negative B-cell or T-cell ALL treated between 2013 and 2024 received either the USC-ALL regimen, a pediatric-inspired protocol incorporating synchronized pegaspargase and high-dose methotrexate during two induction and six consolidation cycles followed by two years of POMP maintenance, or Hyper-CVAD. The cohort was predominantly Hispanic (77.2%) and 33.8% Ph-like, with median age 34 years and median follow-up 40.3 months. The USC-ALL regimen resulted in significantly higher rates of measurable residual disease (MRD) negativity by flow cytometry at complete remission (80.7% vs 50.0%, p = 0.002) and at the end of induction (79.5% vs 54.3%, p = 0.004). Three-year disease-free survival (DFS) favored USC-ALL (62.3% vs 36.7%; HR 2.15, p = 0.004), with a lower cumulative incidence of relapse (CIR; 34.3% vs 57.7%; HR 1.95, p = 0.019) and no difference in overall survival (OS). The DFS advantage remained significant in multivariate analysis adjusting for age, ALL subtype, and end-of-induction MRD status (HR 1.84, p = 0.031). The benefits were most pronounced in patients younger than 40 years and with Ph-like disease, where USC-ALL improved 3-year OS (89.8% vs 59.3%), DFS (65.3% vs 22.0%), and CIR (30.4% vs 68.4%). Pegaspargase toxicities were consistent with previous PIR experience. These results support pediatric-inspired, asparaginase-based regimens as preferred frontline therapy in adult ALL, particularly for Ph-like disease.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。